About Sarepta Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.sarepta.com/
Frequently Asked Questions
What is the 52-week range for SRPT?
The 52-week high is $25.32 and the 52-week low is $14.68.
What is the P/E ratio for SRPT?
The P/E ratio data is currently unavailable.
What is the dividend yield for SRPT?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -9.96%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -6.93%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.98.
Analyst Recommendation Trends
Wall Street analyst consensus for SRPT over the last few months:
Latest SRPT News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., September 30, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on Sept. 30, 2026 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 37 individuals hired by Sarepta in the third quarter of 2026. The equity awards were approved in accordance with Nasdaq Listing Rul
JP Morgan Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20
JP Morgan analyst Anupam Rama maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Neutral and lowers the price target from $23 to $20.
Dyne: Recent Price Drop On Rival's DM1 Data Creates (Risky) 'Buy The Dip' Scenario
Dyne Therapeutics is reiterated as a "risky Buy" following a >30% stock decline, presenting a contrarian opportunity. Click for this DYN stock update.
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne
CAMBRIDGE, Mass., September 30, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today presented new data at the 31st Annual Congress of the World Muscle Society (WMS) that provide evidence of clinically meaningful functional benefit of ELEVIDYS (delandistrogene moxeparvovec) in older ambulatory patients with Duchenne muscular dystrophy.
Sarepta Therapeutics Presents New Data At 31st Annual Congress Of WMS That Provide Evidence Of Clinically Meaningful Functional Benefit Of ELEVIDYS In Older Ambulatory Patients With Duchenne Muscular Dystrophy
Patients treated with delandistrogene moxeparvovec at ages 8-12 demonstrated durable and clinically meaningful benefits across the North Star Ambulatory Assessment and timed function measures over 2 years compared to a
uniQure: Another Selloff On 48-Month Huntington Data; I Am (Marginally) Bullish
uniQure's BLA for AMT-130 is anchored on robust 36-month data, with the FDA signaling willingness to review. Click to read more about the Buy rating for QURE.
Needham Reiterates Underperform on Sarepta Therapeuticsto Underperform
Needham analyst Gil Blum reiterates Sarepta Therapeutics (NASDAQ:SRPT) from Underperform to Underperform.
Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn
In September 2026, REGENXBIO and the University of Pennsylvania settled their patent infringement litigation with Sarepta Therapeutics and Catalent over ELEVIDYS, with Sarepta agreeing to pay US$39.0 million and receiving broad freedom to operate on AAVrh74-based gene therapies under specified patents. The settlement not only closes costly legal disputes but also removes a significant patent overhang on ELEVIDYS and related AAVrh74 programs, potentially clarifying Sarepta’s long-term gene...
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress
CAMBRIDGE, Mass., September 25, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data from its portfolio of treatments for Duchenne muscular dystrophy at the 31st Annual Congress of the World Muscle Society (WMS), taking place Sept. 29 - Oct. 3, in Hiroshima, Japan.
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting
CAMBRIDGE, Mass., September 24, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present new data at the 27th Annual Neuromuscular Study Group (NMSG) Scientific Meeting, taking place Sept. 25-27, 2026, in San Antonio, Texas.
REGENXBIO Says All Ongoing Patent Litigation Regarding Patents-In-Suit To Be Terminated With Prejudice; Agrees Not To Sue Sarepta Or Affiliates Over Existing Elevidys Or AAVrh74-Based Capsids
On September 23, 2026, REGENXBIO Inc. (the "Company") and The Trustees of the University of Pennsylvania ("UPenn") entered into a Settlement Agreement (the "Settlement Agreement") with Sarepta
REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001590877/000119312526399377/rgnx-20260923.htm
Was Moderna Stock's Cancer Vaccine Run Visible In Advance?
Moderna (MRNA) stock rose roughly 510% over the year to September 21, 2026, climbing from about $25 to about $173. The S&P 500 gained 18.5% with dividends reinvested over the same window, and Pfizer (PFE) about 23%. The run's central event came on August 19, 2026, when Merck and Moderna said a Phase III trial of their cancer vaccine, intismeran autogene, met its endpoints in melanoma. A rough timetable for the trial was public long before the stock moved, but its result was not.
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near
Sarepta Therapeutics (NASDAQ:SRPT) outlined plans to stabilize demand for its ELEVIDYS gene therapy while advancing RNA-based programs for facioscapulohumeral muscular dystrophy, or FSHD, and myotonic dystrophy type 1, or DM1, during a Morgan Stanley Global Healthcare Conference fireside chat. Chie
Sarepta Therapeutics, Inc. (SRPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Sarepta Therapeutics, Inc. (SRPT) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 8:30 AM EDTCompany ParticipantsMichael Severino...
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Dyne Therapeutics lead asset z-rostudirsen faces regulatory and confirmatory risks, with FDA approval likely. Find out why DYN stock is a buy.
Novartis Stock Tanks Following Third Major Pipeline Setback
Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.
Novartis shares fall as del-desiran flunks Phase 3 myotonic dystrophy trial
Novartis AG (ADR) (NYSE:NVS) shares fell as much as 10% after the company's del-desiran failed to meet the primary endpoint in its pivotal Phase 3 HARBOR study evaluating the drug in myotonic dystrophy type 1. The study did not show a statistically significant improvement over placebo on...
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.
Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year
CAMBRIDGE, Mass., September 08, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne and five to siblings of individuals living with Duchenne.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Why iSpecimen Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
iSpecimen surged 27.9% premarket on a $4.5M Foldlab AI asset deal; CEA Industries led gainers, while Focus Universal plunged 51.2%.
Why Is Sarepta Therapeutics (SRPT) Up 37% Since Last Earnings Report?
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-04 | Wong Ryan Ho-Yan | -13,272 | $22.22 | $294,904 |
| 2026-09-04 | Rothfuss Cristin | -22,025 | $22.22 | $489,396 |
| 2026-09-04 | Estepan Ian Michael | -24,799 | $22.22 | $551,034 |
| 2026-09-04 | Rodino-Klapac Louise | -21,423 | $22.22 | $476,019 |
| 2026-07-28 | SEVERINO MICHAEL | +2,224,342 | - | - |
| 2026-07-28 | SEVERINO MICHAEL | +756,104 | - | - |
| 2026-06-04 | Chambers Michael Andrew | +16,875 | - | - |
| 2026-06-04 | Mayo Stephen | +16,875 | - | - |
| 2026-06-04 | Boor Kathryn Jean | +16,875 | - | - |
| 2026-06-04 | Nicaise Claude | +16,875 | - | - |
| 2026-06-04 | Barry Richard | +16,875 | - | - |
| 2026-06-04 | Wigzell Hans Lennart Rudolf | +16,875 | - | - |
| 2026-06-04 | Connelly Deirdre P | +16,875 | - | - |
| 2026-06-04 | BEHRENS M KATHLEEN | +16,875 | - | - |
| 2026-03-12 | Mayo Stephen | -7,239 | $17.02 | $123,208 |
| 2026-03-11 | Wong Ryan Ho-Yan | -256 | $17.03 | $4,360 |
| 2026-03-11 | Rothfuss Cristin | -974 | $17.03 | $16,587 |
| 2026-03-11 | Estepan Ian Michael | -1,097 | $17.03 | $18,682 |
| 2026-03-11 | Rodino-Klapac Louise | -948 | $17.03 | $16,144 |
| 2026-03-09 | Wong Ryan Ho-Yan | -113 | $16.95 | $1,915 |
| 2026-03-09 | Wong Ryan Ho-Yan | -162 | $16.95 | $2,746 |
| 2026-03-09 | Rothfuss Cristin | -346 | $16.95 | $5,865 |
| 2026-03-09 | Rothfuss Cristin | -484 | $16.95 | $8,204 |
| 2026-03-09 | Estepan Ian Michael | -583 | $16.95 | $9,882 |
| 2026-03-09 | Estepan Ian Michael | -1,036 | $16.95 | $17,560 |
| 2026-03-09 | Rodino-Klapac Louise | -895 | $16.95 | $15,170 |
| 2026-03-09 | Rodino-Klapac Louise | -504 | $16.95 | $8,543 |
| 2026-03-02 | Wong Ryan Ho-Yan | -450 | $16.2 | $7,290 |
| 2026-03-02 | Rothfuss Cristin | -408 | $16.2 | $6,610 |
| 2026-03-02 | Estepan Ian Michael | -875 | $16.2 | $14,175 |
| 2026-03-02 | Estepan Ian Michael | -3,301 | $16.2 | $53,476 |
| 2026-03-02 | Rodino-Klapac Louise | -767 | $16.2 | $12,425 |
| 2026-03-02 | Rodino-Klapac Louise | -3,718 | $16.2 | $60,232 |
| 2026-03-01 | Estepan Ian Michael | -8,125 | - | - |
| 2026-03-01 | Estepan Ian Michael | +8,125 | - | - |
| 2026-03-01 | Rodino-Klapac Louise | -8,125 | - | - |
| 2026-03-01 | Rodino-Klapac Louise | +8,125 | - | - |
| 2026-02-26 | Estepan Ian Michael | -5,381 | - | - |
| 2026-02-26 | Estepan Ian Michael | -2,069 | - | - |
| 2026-02-26 | Estepan Ian Michael | +5,381 | $13.71 | $73,774 |
| 2026-02-26 | Estepan Ian Michael | +2,069 | $13.71 | $28,366 |
| 2026-02-25 | Estepan Ian Michael | +1,875 | - | - |
| 2026-02-25 | Rodino-Klapac Louise | +1,875 | - | - |
| 2026-01-29 | Nicaise Claude | -10,500 | - | - |
| 2026-01-29 | Nicaise Claude | -6,780 | $21.23 | $143,939 |
| 2026-01-29 | Nicaise Claude | +10,500 | $13.71 | $143,955 |
| 2026-01-27 | BEHRENS M KATHLEEN | +10,500 | - | - |
| 2026-01-27 | BEHRENS M KATHLEEN | -6,494 | $22.17 | $143,972 |
| 2026-01-27 | BEHRENS M KATHLEEN | +10,500 | $13.71 | $143,955 |
| 2025-12-18 | Chambers Michael Andrew | 0 | - | - |
| 2025-12-18 | Chambers Michael Andrew | 0 | - | - |
| 2025-12-16 | Estepan Ian Michael | -13,187 | $22.31 | $294,202 |
| 2025-12-07 | INGRAM DOUGLAS S | +269,542 | - | - |
| 2025-12-07 | INGRAM DOUGLAS S | +96,541 | - | - |
| 2025-12-07 | INGRAM DOUGLAS S | +73,001 | - | - |
| 2025-12-07 | INGRAM DOUGLAS S | +50,000 | - | - |
| 2025-12-07 | INGRAM DOUGLAS S | +50,000 | - | - |
| 2025-12-01 | Wong Ryan Ho-Yan | -78 | $20.96 | $1,635 |
| 2025-12-01 | Wong Ryan Ho-Yan | -80 | $20.96 | $1,677 |
| 2025-11-28 | Rothfuss Cristin | -229 | $21.12 | $4,836 |
| 2025-11-17 | Rodino-Klapac Louise | -4,582 | $18.42 | $84,400 |